---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-012324"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T02:21:58.469469+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q1 revenue down 28% YoY to $237.6M; net loss narrows to $0.02/share

## Summary
- Pharmaceuticals revenue up to $40.4M (vs $36.6M) driven by Rayaldee and IP transfers including $50M Merck upfront.
- Diagnostics revenue plunged to $132.4M from $286.6M due to lower COVID testing and GeneDx sale; operating loss of $40M.
- ModeX entered license deal with Merck for EBV vaccine MDX-2201; potential milestones up to $872.5M plus royalties.
- Net loss improved to $18.3M ($0.02/share) from $55.4M ($0.08/share) in Q1 2022; cash $110.8M not including $50M April payment.
- Rayaldee sales grew to $6.6M from $5.1M; NGENLA approved in 41 countries, sales underway in 17.

## SEC filing metadata
- accession: 0001437749-23-012324
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774923012324/0001437749-23-012324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774923012324/opk20230425_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-012324
- JSON: https://secwatch.observer/filing/0001437749-23-012324.json
- Plain text: https://secwatch.observer/filing/0001437749-23-012324.txt

## Key facts
- Earnings Releases
  OPKO HEALTH, INC. reported the three months ended March 31, 2023 results: revenue $237.6 million, net income $18.3 million, EPS $0.02 per share.
  - Period: the three months ended March 31, 2023
  - Revenue: $237.6 million
  - Net income: $18.3 million
  - EPS: $0.02 per share
  - Result: reported results
  source text: Consolidated total revenues for the first quarter of 2023 were $237.6 million compared with $329.2 million for the comparable period of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000143774923012324/0001437749-23-012324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.